<DOC>
	<DOCNO>NCT00109317</DOCNO>
	<brief_summary>This Phase IIIb , randomize , double-blind , parallel-group , placebo-controlled , multicenter study design evaluate safety tolerability efalizumab administer subcutaneously weekly dos 1.0 mg/kg subject moderate severe plaque psoriasis candidate systemic therapy .</brief_summary>
	<brief_title>A Study Evaluate Raptiva Adults With Moderate Severe Plaque Psoriasis Who Are Candidates Systemic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Signed informed consent Plaque psoriasis cover &gt; =10 % total BSA Diagnosis plaque psoriasis least 6 month Minimal PASI score 12.0 screening In opinion investigator , candidate systemic therapy psoriasis previously treat ( naive systemic treatment ) prior treatment systemic therapy psoriasis ( e.g. , PUVA , cyclosporine , corticosteroid , methotrexate , oral retinoids , MMF , thioguanine , hydroxyurea , sirolimus , azathioprine , 6MP , etanercept ) Body weight &lt; =140 kg 18 75 year old For woman childbearing potential , willingness use acceptable method contraception prevent pregnancy duration study Willingness hold sun exposure reasonably constant avoid use tan booth UV light source study Willingness enter Study ACD2601g Guttate , erythrodermic , pustular psoriasis sole predominant form psoriasis History severe allergic anaphylactic reaction humanize monoclonal antibody fusion protein contain Ig Fc region Clinically significant psoriasis flare screen day randomization History ongoing uncontrolled bacterial , viral , fungal , atypical mycobacterial infection History opportunistic infection ( e.g. , systemic fungal infection , parasite ) Seropositivity human immunodeficiency virus ( HIV ) Pregnancy lactation WBC count &lt; 4000/uL &gt; 14,000/uL Seropositivity hepatitis B C virus Hepatic enzymes &gt; =3x upper limit normal ( ULN ) History active tuberculosis ( TB ) currently undergo treatment TB Presence malignancy within past 5 year , include lymphoproliferative disorder Previous treatment efalizumab ( antiCD11a ) Diagnosis hepatic cirrhosis , regardless cause severity Serum creatinine &gt; =2x ULN Hospital admission cardiac disease , stroke , pulmonary disease within last year History substance abuse within last 5 year Any medical condition , judgment investigator , would jeopardize subject 's safety follow exposure study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Moderate Plaque Psoriasis</keyword>
	<keyword>Severe Plaque Psoriasis</keyword>
	<keyword>Topical</keyword>
</DOC>